News & Events
-
May 9, 2017
Two Arizona leaders in scientific collaboration partner to advance global TB research
May 1, 2017 Two Arizona leaders in scientific collaboration partner to advance global TB research TUCSON and FLAGSTAFF, May 1, 2017 –Two Arizona leaders in worldwide scientific collaboration and infectious disease research have joined forces to improve global tuberculosis (TB) treatment regimens by studying drug resistance. The Bill & Melinda Gates Foundation has...... -
March 23, 2017
CPTR 2017 Workshop: Day 4 – March 23, 2017
The 8th Annual CPTR Initiative Workshop drew more than 150 participants to Washington, D.C. to learn and share information critical to the rapid advancement of new TB combination therapies, drug susceptibility tests (DST), and the tools and models necessary to develop and implement them. Participants represented a diverse group of global stakeholders, including product developers,...... -
March 22, 2017
CPTR 2017 Workshop: Day 3 – March 22, 2017
The 8th Annual CPTR Initiative Workshop drew more than 150 participants to Washington, D.C. to learn and share information critical to the rapid advancement of new TB combination therapies, drug susceptibility tests (DST), and the tools and models necessary to develop and implement them. Participants represented a diverse group of global stakeholders, including product developers,...... -
March 21, 2017
CPTR 2017 Workshop: Day 2 – March 21, 2017
The 8th Annual CPTR Initiative Workshop drew more than 150 participants to Washington, D.C. to learn and share information critical to the rapid advancement of new TB combination therapies, drug susceptibility tests (DST), and the tools and models necessary to develop and implement them. Participants represented a diverse group of global stakeholders, including product developers,...... -
March 20, 2017
2017 CPTR Workshop: Day 1 – March 20, 2017
The 8th Annual CPTR Initiative Workshop drew more than 150 participants to Washington, D.C. to learn and share information critical to the rapid advancement of new TB combination therapies, drug susceptibility tests (DST), and the tools and models necessary to develop and implement them. Participants represented a diverse group of global stakeholders, including product developers, regulators,......